Therapeutical areas

Thanks to its expertise with neuro-hormone receptor antagonists, Rottapharm has contributed to the understanding of the role of the gastrin/CCK system at the central level, with particular regard to its involvement in pain sensations and in anxiety-related behaviour. The specific CCK2 receptor antagonist Itriglumide is currently undergoing clinical studies for its potential application in anxiety disorders.